Alexa Gillman

TL;DR: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.

TL;DR: Target and whole-exome sequencing of serial circulating cell-free DNA samples collected during a phase II trial of olaparib provide predictive, prognostic, response, and resistance data with "second hit" mutations first detectable at disease progression, suggesting clonal evolution from treatment-selective pressure and platinum resistance.

TL;DR: No significant difference was seen in the proportions of patients free from TTR events between the accelerated and standard epirubicin groups, and significantly more patients taking CMF than those taking capecitabine had clinically relevant worsening of quality of life at end of treatment.

TL;DR: It is concluded that multiple biopsies are essential for confident mutational profiling of ER+ breast cancer and TP53 mutations are associated with resistance to oestrogen deprivation therapy.

TL;DR: Recommendations for improving the efficiency of trial conduct within the CTUs network include: further reducing unnecessary bureaucracy in approvals and contracting; improving training for site staff; realistic recruitment targets and appropriate feasibility; developing training across the network.